

To,
The General Manager
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Dear Sir /Madam,

Sub: Recommendations of the Committee of Independent Directors on the Open Offer for acquisition of 15,21,000 Equity Shares of Adline Chem Lab Limited ('Target Company') in terms of Regulation 3(1) and Regulation 4 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Madam,

We, Kunvarji Finstock Private Limited (hereafter referred to as "Manager to the Offer"), are hereby submitting the Recommendations of the Committee of Independent Directors of Adline Chem Lab Limited on the Open Offer for the acquisition of 15,21,000 Equity Shares of Target Company by Mr. Hemant Amrish Parikh ("Acquirer") pursuant to and in compliance with Regulation 3(1) and Regulation 4 of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto.

Request you to take the same on your record.

Thanking You,

For, Kunvarji Finstock Private Limited

Mr. Atul Chokshi

Director (DIN: 00929553) SEBI Reg. No: INM000012564

Encl.: E- Newspaper Copy

Date: September 5, 2023

Place: Ahmedabad



Registered Office: Kunvarji, B - Wing, Siddhivinayak Towers, Off. S.G. Road, Makarba, Ahmedabad - 380 051. Phone:+91 79 6666 9000 | mb@kunvarji.com
Corporate Office: "1208-20, 12th Floor, Summit Business Bay, Opp. PVR Cinema,

Near Western Express Highway – Metro Station, Andheri (E),

Mumbai, Maharashtra - 400093. CIN - U65910GJ1986PTC008979

000762/2023



ADLINE CHEM LAB LIMITED

Registered Office: 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club Nr. Madhur Hotel, S. G. Highway, Bodakdev, Ahmedabad - 380054, India
Tel No.: 91-9227714587; E-mail: info@kamronlabs.in; Website: www.kamronlabs.com

CIN: L24231GJ1988PLC010956

Recommendation of the Independent Director Committee ("IDC") of Adline Chem Lab Limited ("Target Company") in relation to the Open Offer ("Offer") made by Mr. Hemant Amrish Parikh ("Acquirer") to the Public Shareholders of the Target Company ("Shareholders") under Regulations 26(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Subsequent Amendments thereto ("SEBI (SAST) Regulations, 2011").

1	Date	04.00.2022
2	Target Company ("TC")	04.09.2023
3		Adline Chem Lab Limited
3	Details of the Offer pertaining to the	The Offer is being made by the Acquirer pursuant to
1	Target Company	Regulation 3(1) and Regulation 4 of SEBI (SAST)
		Regulations, 2011 for the acquisition up to
		15,21,000 (Fifteen Lakhs Twenty-One Thousand
		Only) Fully Paid-Up Equity Shares of Face Value of
		Rs. 10/- (Rupees Ten Only) Each representing 26%
		('Twenty-Six Percent') of the Fully Paid-Up Equity
L		Share Capital and Voting Capital, payable in Cash.
4		Mr. Hemant Amrish Parikh ("Acquirer")
5	8	Kunvarji Finstock Private Limited
6	The dominated of	1) Mr. Mahendra Popatlal Shah – Independent
	Independent Director	Director, Chairman
	j	2) Mr. Devarshi Dilipbhai Patel – Non-Executive
Н		Independent Director
7	IDC Member's relationship with the	IDC Member's are Independent Directors on the
	Target Company (Director, Equity shares	Board of the Target Company. They do not have any
	owned, any other contract/relationship),	Equity holding in the Target Company. None of them
	if any	have any contractual or other relationships with the
		Target Company other than their position as
		Independent Directors of the Target Company.
8	Trading in the Equity shares/other	No trading in the Equity Shares of the Target
	securities of the TC by IDC Members	Company has been done by IDC Members
9	IDC Member's relationship with the	None of the IDC Members holds any contracts, nor
	Acquirer (Director, Equity shares owned,	have any relationship with the Acquirer.
\square	any other contract/relationship), if any.	•
10	Trading in the Equity shares/other	No trading in the Equity Shares/other securities of
	securities of the Acquirer by ID	the Acquire by IDC Member
11	Recommendation on the Open offer, as to	Based on the review of the Public Announcement
	whether the offer, is or is not, fair and	and the Detailed Public Statement issued by the
	reasonable	Manager to the Offer on behalf of the Acquirer. IDC
		Members believe that the Offer is fair and
	'	reasonable and in line with the SEBI (SAST)
		Regulations, 2011.





1					The shareholders are advised to indep	endently
					evaluate the Open Offer and take an i	informed
					decision, whether or not to tender equity	shares in
\downarrow		,			the open offer.	, , , , , , , , , , , , , , , , , , ,
12	Summary of	reasons	for	the	IDC has taken into consideration the follo	wing for
	recommendation				making the recommendation: IDC has revie	
					a) The Public Announcement ("PA")	
					17.05.2023;	uutcu
					b) The Detailed Public Statement ("DPS") w	hich was
					published on 24.05.2023;	mon was
					c) The Draft Letter of Offer ("DLOF"	dated
					31.05.2023;	,
					d) The Letter of Offer ("LOF") dated 28.08.2	2023.
1					Based on the review of PA, DPS, DLOF	and LOF,
					the IDC Members are of the view that	the Offer
1					Price is in line with the parameters pres	cribed by
					SEBI in the Regulations.	
1					The Equity Shares of the Target Com	pany are
					infrequently traded on BSE Limited (BSI	E) during
1					the Twelve (12) calendar months prece	eding the
					month in which PA was made as set o	ut under
					Regulation 2(1) (j) of SEBI (SAST) Re	guiacion,
1					2011.	ive Point
1					The Offer Price of Rs. 5.25/- (Rupees F Twenty Five Only) per Equity Share is ju	stified in
1					terms of Regulations, 8(1) and 8(2) of	the SEBI
					(SAST) Regulations, 2011 being the high	est of the
					following:	
					Sr. Particulars	Price (in Rs.
						per Equity Share)
					1 The highest negotiated price per Equity Share of	5.25/-
					the Target Company for acquisition under any	
					agreement attracts the obligation to make a PA	
					of an Open Offer. The volume-weighted average price paid or	Not
					navable for acquisitions, by the Acquirer during	Applicable
					52 (Fifty-two) weeks immediately preceding the	
					date of the PA. 3 The highest price paid or payable for any	Not
					acquisition, whether by the acquirer or by any	Applicable
					person acting in concert with him, during the 26 (Twenty-six) weeks immediately preceding the	
					date of the public announcement.	
					4. The volume-weighted average market price of	Not
					such Equity Shares for a period of sixty trading days immediately preceding the date of PA as	Applicable
					traded on an exchange, provided such shares are	
					frequently traded.	Not
					5 The Equity Share value computed under Regulation 8(5) of the Takeover Regulations, if	
					applicable.	
					6 Where the shares are not frequently traded, the price determined by the Acquirer and the	5.21/-
					i inrice determined by the Acquirer and the	1
					Manager to the Offer taking into account	
					Manager to the Offer taking into account valuation parameters including book value,	
					Manager to the Offer taking into account	





	In view of the parameters considered and presented in the table above, in the opinion of acquirers and manager to the offer, the Offer Price is Rs. 5.25/- in terms of Regulation 8(2) of the SEBI (SAST) Regulations, 2011.
13 Details of Independent Advisors, if any.	None
14 Any other matter to be highlighted	None

To the best of our knowledge and belief, after making the proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the Regulations.

Place: Ahmedabad

Date: September 04, 2023

For and on behalf of the Committee of

SIGN.

Adline Chem Lab Limited

Sd/-Mahendra P. Shah Independent Director (DIN: 00461325)

ADLINE CHEM LAB LIMITED

Registered Office: 904, 9th Floor, Shapath-I Complex, Opp. Rajpath Club Nr. Madhur Hotel, S. G. Highway, Bodakdev, Ahmedabad - 380054, India

Tel No.: 91-9227714587; E-mail: info@kamronlabs.in; Website: www.kamronlabs.com

CIN: L24231GJ1988PLC010956

Recommendation of the Independent Director Committee ("IDC") of Adline Chem Lab Limited ("Target Company") in relation to the Open Offer ("Offer") made by Mr. Hemant Amrish Parikh ("Acquirer") to the Public Shareholders of the Target Company ("Shareholders") under Regulations 26(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Subsequent Amendments thereto ("SEBI (SAST) Regulations, 2011").

1	Date	04.09.2023	
2	Target Company ("TC")	Adline Chem Lab Limited	
3	Details of the Offer pertaining to the	The Offer is being made by the Acquirer pursuant	
	Target Company	to Regulation 3(1) and Regulation 4 of SEBI	
		(SAST) Regulations, 2011 for the acquisition up	
		to 15,21,000 (Fifteen Lakhs Twenty-One	
		Thousand Only) Fully Paid-Up Equity Shares of	
		Face Value of Rs. 10/- (Rupees Ten Only) Each	
		representing 26% ('Twenty-Six Percent') of the	
		Fully Paid-Up Equity Share Capital and Voting	
		Capital, payable in Cash.	
4	Acquirer	Mr. Hemant Amrish Parikh ("Acquirer")	
5	Manager to the Offer	Kunvarji Finstock Private Limited	
6	Members of the Committee of	1) Mr. Mahendra Popatlal Shah – Independent	
	Independent Director	Director, Chairman	
		2) Mr. Devarshi Dilipbhai Patel – Non-Executive	
		Independent Director	
7	IDC Member's relationship with the	IDC Member's are Independent Directors on the	
	Target Company (Director, Equity	Board of the Target Company. They do not have	
	shares owned, any other	any Equity holding in the Target Company. None	
	contract/relationship), if any	of them have any contractual or other	
		relationships with the Target Company other	
		than their position as Independent Directors of	
0	Trading in the Equity shapes (ather	the Target Company.	
8	Trading in the Equity shares/other securities of the TC by IDC Members	No trading in the Equity Shares of the Target	
9	IDC Member's relationship with the	Company has been done by IDC Members None of the IDC Members holds any contracts,	
9	Acquirer (Director, Equity shares	nor have any relationship with the Acquirer.	
		nor have any relationship with the Acquirer.	
	owned, any other contract/relationship), if any.		
10		No trading in the Equity Shares/other securities	
10	securities of the Acquirer by ID	of the Acquire by IDC Member	
Ш	securities of the Acquirer by ID	of the Acquire by IDC Melliner	

11	as to whether the offer, is or is not, fair and reasonable	Based on the review of the Public Announcement and the Detailed Public Statement issued by the Manager to the Offer on behalf of the Acquirer. IDC Members believe that the Offer is fair and reasonable and in line with the SEBI (SAST) Regulations, 2011. The shareholders are advised to independently evaluate the Open Offer and take an informed decision, whether or not to tender equity shares in the open offer.
12	recommendation	IDC has taken into consideration the following for making the recommendation: IDC has reviewed a) The Public Announcement ("PA") dated 17.05.2023; b) The Detailed Public Statement ("DPS") which was published on 24.05.2023; c) The Draft Letter of Offer ("DLOF") dated 31.05.2023; d) The Letter of Offer ("LOF") dated 28.08.2023. Based on the review of PA, DPS, DLOF and LOF, the IDC Members are of the view that the Offer Price is in line with the parameters prescribed by SEBI in the Regulations. The Equity Shares of the Target Company are infrequently traded on BSE Limited (BSE) during the Twelve (12) calendar months preceding the month in which PA was made as set out under Regulation 2(1) (j) of SEBI (SAST) Regulation, 2011. The Offer Price of Rs. 5.25/- (Rupees Five Point Twenty Five Only) per Equity Share is justified in terms of Regulations, 8(1) and 8(2) of the SEBI (SAST) Regulations, 2011 being the highest of the following: Sr. Particulars

			_	
			The highest price paid or payable	
			for any acquisition, whether by the	Applicable
			acquirer or by any person acting in	
			concert with him, during the 26	
			(Twenty-six) weeks immediately	
			preceding the date of the public	
			announcement.	
			The volume-weighted average	
			market price of such Equity Shares	Applicable
			for a period of sixty trading days	
			immediately preceding the date of	
			PA as traded on an exchange,	
			provided such shares are frequently	
			traded.	
		5	The Equity Share value computed	Not
			under Regulation 8(5) of the	Applicable
			Takeover Regulations, if applicable.	
		6	Where the shares are not frequently	5.21/-
			traded, the price determined by the	
			Acquirer and the Manager to the	
			Offer taking into account valuation	
			parameters including book value,	
			comparable trading multiples and	
			earnings per share.	
		In	view of the parameters consid	ered and
		•	presented in the table above, in the op-	
			quirers and manager to the offer,	
			ice is Rs. 5.25/- in terms of Regulati	on 8(2) of
			e SEBI (SAST) Regulations, 2011.	
13	Details of Independent Advisors, if	No	one	
	any.			
14	Any other matter to be highlighted	No	one	

To the best of our knowledge and belief, after making the proper enquiry, the information contained in or accompanying this statement is, in all material respect, true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under the Regulations.

Place: Ahmedabad For and on behalf of the Committee of

Date: September 04, 2023 **Adline Chem Lab Limited**

> Sd/-Mahendra P. Shah **Independent Director** (DIN: 00461325)